Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Mar'18 |
---|---|---|---|---|---|---|---|
Research and development ("R&D") expenses, net | |||||||
3,908 | - | - | - | 2,743 | - | - | - |
General and administrative expenses | |||||||
2,058 | - | - | - | 981 | - | - | - |
Operating costs | |||||||
- | - | 618 | 294 | 93 | 15 | 0 | 1 |
Operating Loss | |||||||
-5,966 | -21,199 | -618 | 3,335 | -3,724 | -15 | -0 | -1 |
Finance income, net | |||||||
65 | - | - | - | 499 | - | - | - |
Interest income on marketable securities held in Trust Account | |||||||
- | - | 372 | - | - | - | - | - |
Interest income - other | |||||||
- | - | 2 | - | - | 55 | - | - |
Unrealized loss on marketable securities held in Trust Account | |||||||
- | - | - | - | - | -21 | - | - |
Other income | |||||||
- | - | 374 | - | - | 34 | - | - |
Loss before income tax | |||||||
- | -20,783 | -244 | 114 | 349 | 18 | -0 | -1 |
Income tax | |||||||
- | - | 47 | - | - | 8 | - | - |
Net Loss | |||||||
-5,901 | -20,608 | -292 | 3,562 | -3,225 | 10 | -0 | -1 |
Basic and diluted loss per Ordinary Shares | |||||||
0.26 | 4.06 | -0.25 | -2.35 | 2.20 | 0.00 | 0.00 | 0.00 |
Weighted average number of Ordinary Shares outstanding, basic and diluted | |||||||
22,897 | 15,804 | 2,239 | 2,414 | 2,005 | 1,815 | 1,750 | 1,750 |